Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Colorado Center for Reproductive Medicine
• Treatments: Leuprolide

Criteria

Inclusion Criteria:

• Infertility

• Surgical diagnosis of endometriosis

• Normal ovarian reserve testing

• Regular menses

Exclusion Criteria:

• Irregular menses

• Undiagnosed abnormal uterine bleeding

• Pregnancy

• Prior adverse reaction to any GnRH agonist

• Ovarian cystic or solid mass > 3cm in mean diameter at study entry

• Use of a depot preparation of a GnRh agonist or any hormonal therapy for endometriosis within 6 months of study entry

• Current hepatic, renal, hematologic or psychiatric disorder